Development of Anti-VEGF Prolonged Release Drug Delivery System Containing PLL Dendrimer and Hyaluronic Acid

Basit Öğe Kaydı
dc.authoridGedik, Gülşah/0000-0003-4147-6729;
dc.authorwosidGedik, Gülşah/GWC-6445-2022
dc.authorwosidAyaz, Lokman/K-6716-2013
dc.contributor.authorGedik, G.
dc.contributor.authorOztabag, C. K.
dc.contributor.authorSarp, O.
dc.contributor.authorNazli, H.
dc.contributor.authorTiranbesli, G.
dc.contributor.authorKurt, A. H.
dc.contributor.authorDinc, E.
dc.date.accessioned2024-06-12T10:52:10Z
dc.date.available2024-06-12T10:52:10Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn this study we aimed to develop anti-vascular endothelial growth factors (anti-VEGF) drug delivery systems that long-term sustained release using dendrimer technology and to evaluate its possible cytotoxic effects on the retina pigment epithelial cells (ARPE-19) and the irritation potential by Hen's Egg Test on a chorioallantoic membrane (HET-CAM) analysis. The drug carrier gel formulation was prepared by adding hyaluronic acid (HA) after bevacizumab (BEV) was complexed with poly-L-lysine (PLL) dendrimer. The formulations were determined by the particle size, polydispersity index (PDI) values, zeta potential, pH, optical clarity, and their content. The UV- spectrophotometric analytical methods were developed, validated and applied for the kinetic studies. Prolonged BEV release from formulations has been observed for up to 21 days. Cell viability was evaluated with the XTT assay. VEGF and BEV levels in the medium were measured using a human VEGF and BEV ELISA kit, respectively. HET-CAM assays were conducted to determine the irritation potential. The clarity of gel formulation was found to be clear and satisfactory (double +). The pH of gel formulation ranged between 6.39 and 6.95. The zeta potential of formulations ranged between +3.9 and -1.5 mV. The particle size of formulations ranged between 15 and 302 nm. The loading efficiency (LE) of the complex formulation was found 79.04%. The formulation's kinetic behavior was determined by the Higuchi and Korsmeyer-Peppas model. The formulations did not cause any irritation. According to the results obtained, gel formulation was innovative, effective and suitable for treatment. However, animal experiments and clinical studies should also be performed.en_US
dc.description.sponsorshipTrakya University Scientific Research Projects Unit [2018/196]en_US
dc.description.sponsorshipThis work was supported by Trakya University Scientific Research Projects Unit (Grant no. 2018/196).en_US
dc.identifier.doi10.1134/S1068162022060115
dc.identifier.endpage1361en_US
dc.identifier.issn1068-1620
dc.identifier.issn1608-330X
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85140250100en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage1348en_US
dc.identifier.urihttps://doi.org/10.1134/S1068162022060115
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18603
dc.identifier.volume48en_US
dc.identifier.wosWOS:000870655000013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMaik Nauka/Interperiodica/Springeren_US
dc.relation.ispartofRussian Journal Of Bioorganic Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-VEGFen_US
dc.subjectBevacizumaben_US
dc.subjectPoly-L-Lysine Dendrimeren_US
dc.subjectHyaluronic Aciden_US
dc.subjectHET-CAM Assayen_US
dc.subjectARPE-19en_US
dc.subjectBevacizumab Avastinen_US
dc.subjectIntravitrealen_US
dc.subjectComplexesen_US
dc.titleDevelopment of Anti-VEGF Prolonged Release Drug Delivery System Containing PLL Dendrimer and Hyaluronic Aciden_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu